Takahashi H, Furusato M, Allsbrook W C, Nishii H, Wakui S, Barrett J C, Boyd J
Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina 27709, USA.
Cancer Res. 1995 Apr 15;55(8):1621-4.
The incidence rate of clinically apparent prostatic carcinoma is 8-fold higher in the United States than in Japan, while the prevalence of latent prostatic carcinoma, a presumed precursor to clinical carcinoma, is similar in the two countries. The purpose of this study was to investigate the hypothesis that this profound difference in incidence rates of clinical carcinoma reflects distinct profiles of molecular genetic alterations in the latent precursor lesions that occur in the two countries. A significant fraction of latent carcinomas from Japanese men were found to contain inactivating mutations of the androgen receptor gene, while no such mutations were found in latent carcinomas from American men. No mutations were found in clinical carcinomas from either country. These data offer a potential molecular genetic explanation that may partially account for the distinct prostatic carcinoma incidence rates in these two populations.
美国临床显性前列腺癌的发病率比日本高8倍,而潜在前列腺癌(临床癌的假定前驱病变)的患病率在两国相似。本研究的目的是调查这样一种假设,即临床癌发病率的这种显著差异反映了两国潜在前驱病变中分子遗传改变的不同特征。发现相当一部分日本男性的潜在癌含有雄激素受体基因的失活突变,而美国男性的潜在癌中未发现此类突变。来自任何一个国家的临床癌中均未发现突变。这些数据提供了一种潜在的分子遗传学解释,可能部分解释了这两个人群中前列腺癌发病率的差异。